Posted on July 23, 2019
"In an open-label study of women in southern and eastern Africa, a vaginal ring that is inserted once a month and slowly releases an antiviral drug was estimated to reduce the risk of HIV by 39%, according to statistical modeling. In addition, the study found that participants appeared to use the ring more in the open-label study than in a previous clinical trial. These and other results of the HIV Open Label Extension (HOPE) study were presented today at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico City."
"In 2017 alone, nearly 870,000 women and girls acquired HIV, according to UNAIDS. Currently available forms of HIV prevention for women are limited, and many women are unable to negotiate condom use with male sexual partners. The vaginal ring tested in the HOPE study, which continuously releases the anti-HIV drug dapivirine, was designed to be a discreet, long-acting HIV prevention option for women. The wearer replaces the product herself once every four weeks. The dapivirine vaginal ring is currently under regulatory review with the European Medicines Agency."